A heart failure drug to treat leukaemia: a promising new therapeutic approach
Canadian researchers followed their intuition that a drug initially intended for heart failure could be…
Browsing: Leukaemia
EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities
The current standard of care for patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions…
EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?
Acute myeloid leukaemia (AML) is a rare, highly fatal blood cancer. Allogeneic haematopoietic cell transplantation…
EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive cancer which is lethal to 15% of…
EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia
The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed…
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown…
Towards a safer treatment for leukaemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the…
Patterns of chronic lymphocytic leukaemia growth identified
In patients with chronic lymphocytic leukaemia (CLL), the rate of disease growth is apt to…
Recovery twice as hard for survivors of childhood acute lymphoblastic leukaemia
Nearly 90 per cent of children with acute lymphoblastic leukaemia (ALL) survive, yet the same…
Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…